08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Nuo Therapeutics dermatology news

Nuo filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. The company markets its Aurix System in the U.S. The device that produces topical platelet-rich plasma (PRP) gel from...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

Aurix System: Phase IV started

Nuo began the open-label, U.S. Phase IV Au Study to compare Aurix System plus standard of care (SOC) vs. SOC alone in about 760 patients with diabetic foot ulcers, 640 patients with venous leg ulcers...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Company News

Nuo Therapeutics sales and marketing update

Nuo Therapeutics (formerly Cytomedix Inc. ) re-launched its AutoloGel System in the U.S. under the Aurix System brand. The device produces topical platelet-rich plasma (PRP) gel from a patient's own blood and has been approved...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Clinical News

AutoloGel System regulatory update

Cytomedix said the Centers for Medicare & Medicaid Services (CMS) issued final rules covering reimbursement for Cytomedix's AutoloGel System, which isolates and activates platelet-rich plasma (PRP) from a patient's own blood and is then used...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

Cytomedix dermatology news

Cytomedix will restructure R&D to reduce cash burn and focus on commercializing AutoloGel for chronic wound care. By year end, the company will "substantially" conclude its financial support of the Phase II RECOVER-Stroke trial with...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

AutoloGel System regulatory update

Cytomedix said the Centers for Medicare & Medicaid Services (CMS) proposed guidelines covering Medicare reimbursement for its AutoloGel System, which isolates and activates platelet-rich plasma (PRP) from a patient's own blood and is then used...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

AutoloGel System regulatory update

Cytomedix said the Centers for Medicare & Medicaid Services (CMS) granted formal approval for Medicare reimbursement of autologous platelet-rich plasma (PRP) gel to treat chronic, non-healing diabetic, venous and/or pressure wounds under CMS's coverage with...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Angel Concentrated Platelet Rich Plasma System regulatory update

Cytomedix said it received CE Mark approval in the EU for its Angel Concentrated Platelet Rich Plasma System to prepare platelet rich plasma (PRP) from blood and bone marrow aspirate. The system is now approved...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

AutoloGel System regulatory update

Cytomedix said the Centers for Medicare & Medicaid Services (CMS) issued a final decision memo supporting coverage of autologous platelet-rich plasma (PRP) gel under its coverage with evidence development (CED) mechanism to treat chronic, non-healing...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Company News

Cytomedix deal

Cytomedix extended to Aug. 30 an exclusive period for an undisclosed company to further negotiate the terms of a hospital distribution deal for CytoMedix's AutoloGel System . Cytomedix said the agreement will include options to...